Half Year 2020 Allergy Therapeutics PLC Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Allergy Therapeutics Interim Results for the 6 months ended 31st of December 2019 Conference Call. (Operator Instructions) As a reminder, today's call is being recorded today, and you will hear music until the presentation begins.
Hello, everybody, hello all the people on the phone, and thank you very much for coming today for the interim results announcement. This is Manuel Llobet, the CEO, and we have today with us Nick Wykeman, our CFO; and Alan Bullimore, our Head of Strategic Communications. I'm very glad to take you through the half year results. So at the end of the presentation, we'll have questions from people in the room and from people outside the room.
So let's start with the financial and operational highlights. We grew 9% in constant currency, achieving a revenue of GBP 50.5 million compared to GBP 46.7 million last year. We increased 10% our operating profit pre R&D. We reached a cash balance of almost GBP 40
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |